**FORM      10-QSB**

**SECURITIES      AND EXCHANGE COMMISSION**

**Washington,      D.C. 20549**

| (Mark                One)   |   |                                                                                                                            |
|----------------------------------|--------|---------------------------------------------------------------------------------------------------------------------------------|
| x                                |   | **QUARTERLY                REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE                ACT OF 1934** |

|   |   |                                                                                                                             |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------|
| o      |   | **TRANSITION                REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE                ACT OF 1934** |

**000-29462**

**ADVANCED      PLANT PHARMACEUTICALS, INC.**

----

| Delaware                                                                                    |   | 59-2762023                                                        |
|---------------------------------------------------------------------------------------------|--------|-------------------------------------------------------------------|
| (State                or other jurisdiction ofincorporation                or organization) |   | (I.R.S.                EmployerIdentification                No.) |
|                                                                                        |   |                                                              |
| 43                West 33rd                StreetNew                York, NY                |   | 10001                                                             |
| (Address                of principal executive office)                                      |   | (Zip                Code)                                         |
|                                                                                        |   |                                                              |
| Registrant’s                telephone number, including area code:                    |   | (212)695-3334                                                     |

----

----

----

**INDEX**

**PART        I. - FINANCIAL INFORMATION**

| Item                  1. Financial Statements | 4                                                                                                                                                                                  |
|-----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                          |                                                                                                                                                                               |   |
|                                          | Consolidated                  Balance Sheets at September 30, 2007 (unaudited) and December 31,                  2006                                                              | F-1 |
|                                          |                                                                                                                                                                               |   |
|                                          | Consolidated                  Statements of Operations for the Three and Nine Months Ended September                  30,                  2007 and September 30, 2006 (unaudited) | F-2 |
|                                          |                                                                                                                                                                               |   |
|                                          | Consolidated                  Statements of Cash Flows for the Nine Months Ended September 30,                  2007 and                  September 30, 2006 (unaudited)           | F-3 |
|                                          |                                                                                                                                                                               |   |
|                                          | Notes                  to Financial Statements as of September 30, 2007                                                                                                            | F-4 |
|                                          |                                                                                                                                                                               |   |
| Item                  2                       | Management’s                  Discussion and Analysis or Plan of Operations                                                                                                  | 5 |
|                                          |                                                                                                                                                                               |   |
| Item                  3                       | Controls                  and Procedures                                                                                                                                           | 7 |

**PART        II. - OTHER INFORMATION**

| Item                  1 | Legal                  Proceedings                                           | 8      |
|-------------------------|------------------------------------------------------------------------------|--------|
|                    |                                                                         |   |
| Item                  2 | Unregistered                  Sales of Equity Securities and Use of Proceeds | 8      |
|                    |                                                                         |   |
| Item                  3 | Defaults                  upon senior securities                             | 8      |
|                    |                                                                         |   |
| Item                  4 | Submission                  of matters to a vote of security holders         | 8      |
|                    |                                                                         |   |
| Item                  5 | Other                  information                                           | 8      |
|                    |                                                                         |   |
| Item                  6 | Exhibits                  and reports on Form 8-K                            | 8      |

----

**PART      I. FINANCIAL INFORMATION**

**INDEX      TO FINANCIAL STATEMENTS**

| Consolidated                  Balance Sheets                | F-1    |
|-------------------------------------------------------------|--------|
|                                                        |   |
| Consolidated                  Statements of Operations      | F-2    |
|                                                        |   |
| Consolidated                  Statements of Cash Flows      | F-3    |
|                                                        |   |
| Notes                  to Consolidated Financial Statements | F-5    |

----

| ADVANCED                  PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES |
|------------------------------------------------------------------------|
| CONSOLIDATED                  BALANCE SHEETS                           |

|                                                                                                                       |   | September                  30, |        | December                  31,  |   |
|----------------------------------------------------------------------------------------------------------------------------|--------|--------------------------------|-------------|-------------------------------------|--------|
|                                                                                                                       |   | 2007                           |        | 2006                           |   |
|                                                                                                                       |   | Unaudited                      |        |                           |   |
| ASSETS                                                                                                                     |   |                           |        |                                |   |   |   |
| CURRENT                  ASSETS                                                                                            |   |                           |        |                                |   |   |   |
| Prepaid                  consulting expenses                                                                               |   | $                              | -           |                                | $      | 7,600 |   |
|  Total                  Current Assets                                                                                |   |                           | -           |                                |   | 7,600 |   |
|                                                                                                                       |   |                           |        |                                |   |   |   |
| OFFICE                    EQUIPMENT, net of accumulated depreciation of $4,353 and $4,058,                    respectively |   |                           | -           |                                |   | 295 |   |
|                                                                                                                       |   |                           |        |                                |   |   |   |
| OTHER                  ASSETS                                                                                              |   |                           |        |                                |   |   |   |
| Goodwill                                                                                                                   |   |                           | 328,648     |                                |   | - |   |
| Due                  from related companies                                                                                |   |                           | 7,120       |                                |   | 16,120 |   |
| Other                  assets                                                                                              |   |                           | 5,479       |                                |   | 5,679 |   |
|  Total                  Assets                                                                                        |   | $                              | 341,247     |                                | $      | 29,694 |   |
|                                                                                                                       |   |                           |        |                                |   |   |   |
| LIABILITIES                  AND STOCKHOLDERS' DEFICIENCY                                                                  |   |                           |        |                                |   |   |   |
| CURRENT                  LIABILITIES                                                                                       |   |                           |        |                                |   |   |   |
| Bank                  overdraft                                                                                            |   | $                              | 6,062       |                                | $      | 5,468 |   |
| Accounts                  payable                                                                                          |   |                           | 205,866     |                                |   | 181,946 |   |
| Accrued                  payroll taxes                                                                                     |   |                           | 413,331     |                                |   | 299,194 |   |
| Accrued                  expenses                                                                                          |   |                           | 10,300      |                                |   | 126,500 |   |
| Accrued                  expenses payable in common stock                                                                  |   |                           | 119,096     |                                |   | - |   |
| Accrued                  expenses - stockholders                                                                           |   |                           | 1,057,370   |                                |   | 871,549 |   |
| Due                  to related companies                                                                                  |   |                           | 11,882      |                                |   | 8,484 |   |
| Deposit                  to acquire stock                                                                                  |   |                           | 100,000     |                                |   | - |   |
| Acquisition                  payable in common stock                                                                       |   |                           | 300,000     |                                |   | - |   |
| Loans                  payable                                                                                             |   |                           | 99,000      |                                |   | - |   |
| Loans                  payable - stockholders                                                                              |   |                           | 338,040     |                                |   | 305,993 |   |
|  Total                  Current Liabilities                                                                           |   |                           | 2,660,947   |                                |   | 1,799,134 |   |
|                                                                                                                       |   |                           |        |                                |   |   |   |
| STOCKHOLDERS'                  DEFICIENCY                                                                                  |   |                           |        |                                |   |   |   |
| Preferred                  stock, authorized 10,000,000 shares;                                                            |   |                           |        |                                |   |   |   |
| $0.0007                  par value; 5,000,000 shares issued and                                                       |   |                           |        |                                |   |   |   |
| outstanding                  at September 30, 2007 and December 31, 2006                                              |   |                           | 3,500       |                                |   | 3,500 |   |
| Common                  stock, authorized 880,000,000 shares;                                                              |   |                           |        |                                |   |   |   |
| $0.0007                  par value; 880,000,000 and 875,157,996                                                       |   |                           |        |                                |   |   |   |
| shares                  issued and outstanding at September 30, 2007                                                  |   |                           |        |                                |   |   |   |
| and                  December 31, 2006, respectively                                                                  |   |                           | 616,000     |                                |   | 612,611 |   |
| Additional                  paid-in capital                                                                                |   |                           | 22,163,268  |                                |   | 21,982,453 |   |
| Accumulated                  deficit                                                                                       |   |                           | (25,102,468 | )                                   |   | (24,368,004 | ) |
| TotalStockholders'                  Deficiency                                                                             |   |                           | (2,319,700  | )                                   |   | (1,769,440 | ) |
|  Total                  Liabilities and Stockholders' Deficiency                                                      |   | $                              | 341,247     |                                | $      | 29,694 |   |

| See                  accompanying notes to financial statements. |
|------------------------------------------------------------------|

----

| ADVANCED                  PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES              |
|-------------------------------------------------------------------------------------|
| CONSOLIDATED                  STATEMENTS OF OPERATIONS                  (UNAUDITED) |

|                                                          |   |  For                  the Three Months ended September 30,   |        |  For                  the Nine Months ended September 30,   |   |
|---------------------------------------------------------------|--------|-----------------------------------------------------------------------------|-------------|----------------------------------------------------------------------------|--------|
|                                                          |   |  2007                                                                  |        |  2006                                                            |   |  2007  |   |  2006  |   |
|                                                          |   |                                                                   |        |                                                                  |   |    |   |    |   |
| REVENUE                  - SALES                              |   | $                                                                           | 657         |                                                                       | $      | 3,224 |   | $ | 4,879 |   | $ | 7,775 |   |
|                                                          |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
| COSTS                  AND EXPENSES                           |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
| Cost                  of goods sold                           |   |                                                                        | 1,800       |                                                                       |   | 3,450 |   |   | 2,378 |   |   | 3,450 |   |
| Salaries                  and consulting fees - officers      |   |                                                                        | 79,500      |                                                                       |   | 5,369,241 |   |   | 238,500 |   |   | 5,528,241 |   |
| Selling,                  general and administrative expenses |   |                                                                        | 49,732      |                                                                       |   | (6,252 | ) |   | 498,063 |   |   | 192,941 |   |
| Depreciation                                                  |   |                                                                        | -           |                                                                       |   | 279 |   |   | 295 |   |   | 837 |   |
|                                                          |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
|  Total                  Costs and Expenses               |   |                                                                        | 131,032     |                                                                       |   | 5,366,718 |   |   | 739,236 |   |   | 5,725,469 |   |
|                                                          |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
| NET                  OPERATING LOSS                           |   |                                                                        | (130,375    | )                                                                          |   | (5,363,494 | ) |   | (734,357 | ) |   | (5,717,694 | ) |
|                                                          |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
| OTHER                  INCOME (EXPENSE)                       |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
| Gain                  on sale of investment                   |   |                                                                        | -           |                                                                       |   | - |   |   | - |   |   | 69,500 |   |
| Interest                  expense                             |   |                                                                        | (39         | )                                                                          |   | (220 | ) |   | (107 | ) |   | (4,388 | ) |
|                                                          |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
|  Net                  Other Income (Expense)             |   |                                                                        | (39         | )                                                                          |   | (220 | ) |   | (107 | ) |   | 65,112 |   |
|                                                          |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
| LOSS                  BEFORE DISCONTINUED                     |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
| OPERATIONS                                                    |   |                                                                        | (130,414    | )                                                                          |   | (5,363,714 | ) |   | (734,464 | ) |   | (5,652,582 | ) |
| Loss                  from discontinued operations            |   |                                                                        | -           |                                                                       |   | (1,805,778 | ) |   | - |   |   | (2,471,156 | ) |
|                                                          |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
| NET                  LOSS                                     |   | $                                                                           | (130,414    | )                                                                          | $      | (7,169,492 | ) | $ | (734,464 | ) | $ | (8,123,738 | ) |
|                                                          |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
|                                                          |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
| NET                  LOSS PER SHARE OF COMMON STOCK           |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
| Loss                  before discontinued operations          |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
|  (basic                  and fully diluted)              |   | $                                                                           | -           |                                                                       | $      | (0.01 | ) | $ | - |   | $ | (0.01 | ) |
|                                                          |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
| Net                  loss (basic and fully diluted)           |   | $                                                                           | -           |                                                                       | $      | (0.01 | ) | $ | - |   | $ | (0.01 | ) |
|                                                          |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
|                                                          |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
| WEIGHTED                  AVERAGE NUMBER OF                   |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
| COMMON                  SHARES OUTSTANDING                    |   |                                                                        |        |                                                                       |   |   |   |   |   |   |   |   |   |
|  (basic                  and fully diluted)              |   |                                                                        | 880,000,000 |                                                                       |   | 798,157,996 |   |   | 879,933,968 |   |   | 798,157,996 |   |

| See                  accompanying notes to financial statements. |
|------------------------------------------------------------------|

----

| ADVANCED                  PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES              |
|-------------------------------------------------------------------------------------|
| CONSOLIDATED                  STATEMENTS OF CASH FLOWS                  (UNAUDITED) |

|                                                                       |   |  For                  the Nine Months Ended September                  30,    |     |
|----------------------------------------------------------------------------|--------|---------------------------------------------------------------------------------------------------|----------|
|                                                                       |   |  2007                                                                                        |     |  2006 |   |
| CASH                  FLOWS FROM OPERATING ACTIVITIES                      |   |                                                                                              |     |   |   |   |   |
| Net                  loss                                                  |   | $                                                                                                 | (734,464 | ) | $ | (8,123,738 | ) |
| Adjustments                  to reconcile net loss to cash flows           |   |                                                                                              |     |   |   |   |   |
| from                  operating activities:                           |   |                                                                                              |     |   |   |   |   |
|  Stock                  issued for services                           |   |                                                                                              | 267,300  |   |   | 1,947,500 |   |
|  Gain                  on sale of investment                          |   |                                                                                              | -        |   |   | (69,500 | ) |
|  Stock                  held for investment issued for services       |   |                                                                                              | -        |   |   | 5,289,741 |   |
|  Depreciation                  expense                                |   |                                                                                              | 295      |   |   | 837 |   |
| Changes                  in assets and liabilities:                        |   |                                                                                              |     |   |   |   |   |
| Decrease                  in accounts receivable                      |   |                                                                                              | -        |   |   | 1,188 |   |
| Decrease                  in prepaid expenses - officers              |   |                                                                                              | -        |   |   | 31,550 |   |
| Decrease                  in prepaid consulting expenses              |   |                                                                                              | 7,600    |   |   | - |   |
| Decrease                  (increase) in due from related companies    |   |                                                                                              | 9,000    |   |   | (4,500 | ) |
| Increase                  in accounts payable                         |   |                                                                                              | 64,120   |   |   | 72,727 |   |
| Increase                  in accrued payroll taxes                    |   |                                                                                              | 114,137  |   |   | 75,100 |   |
| Increase                  (decrease) in accrued expenses              |   |                                                                                              | (116,200 | ) |   | 58,303 |   |
| Increase                  in accrued expenses - stockholders          |   |                                                                                              | 201,821  |   |   | 371,218 |   |
| Increase                  in due to related companies                 |   |                                                                                              | 3,398    |   |   | - |   |
|  Net                  cash used in operating activities               |   |                                                                                              | (182,993 | ) |   | (349,574 | ) |
|                                                                       |   |                                                                                              |     |   |   |   |   |
| CASH                  FLOWS FROM INVESTING ACTIVITIES                      |   |                                                                                              |     |   |   |   |   |
| Proceeds                  from disposition of stock held for investment    |   |                                                                                              | -        |   |   | 65,000 |   |
|  Net                  cash provided by investing activities           |   |                                                                                              | -        |   |   | 65,000 |   |
|                                                                       |   |                                                                                              |     |   |   |   |   |
| CASH                  FLOWS FROM FINANCING ACTIVITIES                      |   |                                                                                              |     |   |   |   |   |
| Cash                  received in acquisition of subsidiary                |   |                                                                                              | 1,417    |   |   | - |   |
| Bank                  overdraft                                            |   |                                                                                              | 594      |   |   | 2,055 |   |
| Proceeds                  from deposits to acquire stock                   |   |                                                                                              | 50,000   |   |   | 52,275 |   |
| Proceeds                  from loans payable                               |   |                                                                                              | 99,000   |   |   | - |   |
| Proceeds                  from loans payable - stockholders                |   |                                                                                              | 34,832   |   |   | 12,599 |   |
| Payments                  on loans payable - stockholders                  |   |                                                                                              | (2,850   | ) |   |   |   |
| Proceeds                  from issuance of former subsidiay's common stock |   |                                                                                              | -        |   |   | 206,000 |   |
|  Net                  cash provided by financing activities           |   |                                                                                              | 182,993  |   |   | 272,929 |   |
|                                                                       |   |                                                                                              |     |   |   |   |   |
|  Net                  decrease in cash                                |   |                                                                                              | -        |   |   | (11,645 | ) |
|                                                                       |   |                                                                                              |     |   |   |   |   |
| CASH                  AT BEGINNING OF PERIOD                               |   |                                                                                              | -        |   |   | 11,688 |   |
|                                                                       |   |                                                                                              |     |   |   |   |   |
| CASH                  AT END OF PERIOD                                     |   | $                                                                                                 | -        |   | $ | 43 |   |

| See                  accompanying notes to financial statements. |
|------------------------------------------------------------------|

----

| ADVANCED                  PLANT PHARMACEUTICALS, INC. AND SUBSIDIARIES                          |
|-------------------------------------------------------------------------------------------------|
| CONSOLIDATED                  STATEMENTS OF CASH FLOWS (UNAUDITED)                  (CONTINUED) |

|                                                                                                    |   |  For                  the Nine Months Ended September 30,   |     |
|---------------------------------------------------------------------------------------------------------|--------|----------------------------------------------------------------------------|----------|
|                                                                                                    |   |  2007                                                                 |     |  2006 |   |
| SUPPLEMENTAL                  DISCLOSURE OF CASH FLOW INFORMATION                                       |   |                                                                       |     |   |   |   |   |
| CASH                  PAID FOR:                                                                         |   |                                                                       |     |   |   |   |   |
| Interest                                                                                                |   | $                                                                          | 107      |   | $ | 4,388 |   |
|                                                                                                    |   |                                                                       |     |   |   |   |   |
|                                                                                                    |   |                                                                       |     |   |   |   |   |
| NON-CASH                  INVESTING AND FINANCING ACTIVITIES:                                           |   |                                                                       |     |   |   |   |   |
| Issuance                  of common stock as compensation                                               |   |                                                                       | 267,300  |   |   | - |   |
| Issuance                  of Mazal common stock for services classified as                              |   |                                                                       |     |   |   |   |   |
| a                  deferred credit                                                                 |   |                                                                       | -        |   |   | 1,947,500 |   |
| Miscellaneous                  receivable from sale of stock held for investment                        |   |                                                                       | -        |   |   | 5,000 |   |
| Issuance                  of stock held for investment in payment of                                    |   |                                                                       |     |   |   |   |   |
| accrued                  expenses - stockholders                                                   |   |                                                                       | 16,000   |   |   | 455,550 |   |
| Issuance                  of stock held for investment in payment of                                    |   |                                                                       |     |   |   |   |   |
| due                  to stockholder - asset acquisition                                            |   |                                                                       | -        |   |   | 1,315,000 |   |
| Issuance                  of stock held for investment in payment of                                    |   |                                                                       |     |   |   |   |   |
| loans                  payable - stockholders                                                      |   |                                                                       | -        |   |   | 13,709 |   |
| Gain                  on stock held for investment transferred to related                  parties      |   |                                                                       |     |   |   |   |   |
| in                  payment of debt classified as additional paid-in                  capital      |   |                                                                       | -        |   |   | 7,072,005 |   |
| Issuance                  of common stock in satisfaction of                                            |   |                                                                       |     |   |   |   |   |
| accounts                  payable                                                                  |   |                                                                       | 40,200   |   |   | - |   |
| Common                  stock in excess of authorized number of shares                                  |   |                                                                       |     |   |   |   |   |
| reclassified                  to accrued expenses payable in common stock                          |   |                                                                       | 119,096  |   |   | - |   |
| Common                  stock in excess of authorized number of shares                                  |   |                                                                       |     |   |   |   |   |
| reclassified                  to deposits to acquire common stock                                  |   |                                                                       | 50,000   |   |   | - |   |
| Assets                  acquired and liabilities assumed in acquisition of                  subsidiary: |   |                                                                       |     |   |   |   |   |
| Cash                                                                                               |   |                                                                       | 1,417    |   |   | - |   |
| Due                  from related company                                                          |   |                                                                       | 5,618    |   |   | - |   |
| Goodwill                                                                                           |   |                                                                       | 328,648  |   |   | - |   |
| Loans                  payable - stockholders                                                      |   |                                                                       | (5,683   | ) |   | - |   |
| Acquisition                  payable in common stock                                               |   |                                                                       | (300,000 | ) |   | - |   |
| Issuance                  of common stock                                                          |   |                                                                       | (30,000  | ) |   | - |   |

| See                  accompanying notes to financial statements. |
|------------------------------------------------------------------|

----

| 1. | CONDENSED                  FINANCIAL STATEMENTS |
|----|-------------------------------------------------|

| 2. | PRINCIPLES                  OF CONSOLIDATION |
|----|----------------------------------------------|

| 3. | COMMITMENTS                  AND CONTINGENCIES |
|----|------------------------------------------------|

----

| 4. | ACCRUED                  EXPENSES PAYABLE IN COMMON STOCK |
|----|-----------------------------------------------------------|

| 5. | DEPOSITS                  TO ACQUIRE STOCK |
|----|--------------------------------------------|

| 6. | LOANS                  PAYABLE |
|----|--------------------------------|

----

| 7. | ISSUANCE                  OF COMMON STOCK |
|----|-------------------------------------------|

----

| 8. | GOING                  CONCERN UNCERTAINTY AND MANAGEMENT’S                  PLANS |
|----|------------------------------------------------------------------------------------------|

| 9. | RECLASSIFICATIONS |
|----|-------------------|

----

| Item              1A. | RISK                FACTORS |
|-----------------------|-----------------------------|

| Item              2. | Management’s                Discussion and Analysis of Financial Condition and Results of                Operation  |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|

----

**Comparison      of Operating Results for the three and nine months ended September 30, 2007      and      September 30, 2006. **

----

| ITEM              3. | CONTROLS                AND PROCEDURES |
|----------------------|----------------------------------------|

----

Item 5.      Exhibits and Report on Form 8-K 

| Exhibit                  No. | Description                                                                                                 |
|------------------------------|-------------------------------------------------------------------------------------------------------------|
|                         |                                                                                                        |
| 31.1                         | Section                  302 Certification of the Principal Executive Officer *                             |
|                         |                                                                                                        |
| 31.2                         | Section                  302 Certification of the Principal Financial Officer *                             |
|                         |                                                                                                        |
| 32.1                         | Section                  906 Certification of Principal Executive Officer *                                 |
|                         |                                                                                                        |
| 32.2                         | Section                  906 Certification of Principal Financial and Accounting Officer                  * |

----

 SIGNATURES

|                                 |                                                           |                                  |
|--------------------------------------|----------------------------------------------------------------|---------------------------------------|
|                                 | ADVANCED              PLANT              PHARMACEUTICALS, INC. |
|                            |                                                      |                             |
| Date:              November 19, 2007 | By:                                                  | /s/ David              Lieberman |
|                                 | David                LiebermanCEO                and Director  |
|                                 |                                                           |

| By:  | /s/ David Lieberman                                      | Date: November 19, 2007 |
|-----------|---------------------------------------------------------------|-------------------------|
|      | David                LiebermanCEO                and Director |                    |

----